Health risks do not arrive in neat categories. They emerge, overlap, and compound across a lifetime—sometimes before symptoms appear, sometimes through years of chronic management, and sometimes through complex treatment.
Boston Oncology’s Lifetime Health Stack™ organizes our portfolio around five connected layers of health: Cancer, Chronic Inflammation, Metabolic Health, Lipids and Cardiovascular Risk, and Neurocognitive Health.
Together, these layers span prevention, long-term disease management, and complex treatment—one connected strategy for the medicines that shape health across a lifetime.
The Lifetime Health Stack is grounded in the realities of patient care and healthcare delivery—not an abstract list of therapeutic categories.
Boston Oncology’s proximity to clinical use, procurement systems, and inventory patterns helps the company recognize emerging needs before they are fully expressed in formal demand signals. That intelligence guides the selection of medicines for which localization can materially improve availability, supply continuity, and sustained adoption.
Across the GCC and wider MENA region, these medicines address a chronic-risk burden Boston Oncology estimates at nearly US$1 trillion in direct and indirect costs over the next 10–15 years.*
*Boston Oncology management estimate based on a synthesis of publicly available regional disease-burden, healthcare-cost, and productivity data. Represents projected aggregate direct and indirect costs across the GCC and wider MENA region over the next 10–15 years.
Boston Oncology established its operating foundation in cancer, where delivering complex medicines requires exceptional coordination across regulation, manufacturing, supply, market access, and clinical use.
That foundation now extends across additional layers of health—supporting earlier intervention, sustained treatment, and the long-term management of risks and conditions that can shape a person’s health over decades.
The foundation. The demands of cancer care established the regulatory, manufacturing, and supply disciplines required to deliver complex medicines reliably.
Sustaining care over time. Biosimilars extend access in conditions often managed for years, where affordability and reliable supply can determine whether treatment is maintained.
Expanding access earlier. A launched incretin medicine and next-generation incretin programs extend the portfolio into widespread metabolic conditions that can influence health across a lifetime. Integrated cartridge filling and pen assembly support access at scale.
Making prevention easier to sustain. A long-acting lipid-lowering program with twice-yearly maintenance dosing responds to a fundamental challenge: people may struggle to remain on treatment for risks they cannot feel.
Preparing for future need. Neurocognitive disease is a growing source of lifetime burden for patients, caregivers, and health systems. Early identification, specialist pathways, affordability, and reliable supply will help determine whether emerging innovation reaches patients.
Selected medicines from Boston Oncology’s portfolio—reflecting our commitment to quality, reliable supply, and patient care.
Semaglutide
1.34 mg/mL | Solution for injection in a pre-filled pen
Adalimumab
40 mg/0.8 mL | Solution for injection
Tocilizumab
Multiple strengths and presentations
Enoxaparin sodium
Multiple strengths | Solution for injection
Medicines should be used only as directed by a qualified healthcare professional. Product availability, approved indications, and regulatory status may vary by market.
For questions about a medicine, speak with your physician or pharmacist. To report a suspected adverse event, medication error, lack of effectiveness, or product-quality concern, use Boston Oncology Arabia’s pharmacovigilance reporting service.
